Age-related changes in durability and function of vaccine-elicited influenza-specific CD4 + T-cell responses

Vaccine

Volumn 29, Issue 47, 2011, Pages 8606-8614

  Mahnke, Yolanda D ^a   Saqr, Areej ^b   Hazenfeld, Staci ^b   Brady, Rebecca C ^b   Roederer, Mario ^a   Subbramanian, Ramu A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Durability; Hemagglutinin; Proliferation; T cell quality

Indexed keywords

GAMMA INTERFERON; INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ADULT; AGE; AGED; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; INFLUENZA; LYMPHOCYTE FUNCTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INTERFERON-GAMMA; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 82455175303     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.019     Document Type: Article

References (62)

1. Palese P. Influenza: old and new threats. Nat Med 2004, 10:S82-S87.
2. WHO Global Alert and Response (GAR): pandemic (H1N1) 2009 - update 112 2010.
3. Koopmans M., Wilbrink B., Conyn M., Natrop G., van der Nat H., Vennema H., et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004, 363:587-593.
4. Webster R.G., Hulse D.J. Microbial adaptation and change: avian influenza. Rev Sci Tech 2004, 23:453-465.
5. Subbarao K., Katz J. Avian influenza viruses infecting humans. Cell Mol Life Sci 2000, 57:1770-1784.
6. Normile D. Infectious diseases. Genetic analyses suggest bird flu virus is evolving. Science 2005, 308:1234-1235.
7. Couch R.B., Kasel J.A. Immunity to influenza in man. Annu Rev Microbiol 1983, 37:529-549.
8. Delem A. Serum SRH antibody level as a measure of the immunity against natural and artificial A/Victoria/3/75 infections. Dev Biol Stand 1977, 39:391-396.
9. Goodeve A., Potter C.W., Clark A., Jennings R., Schild G.C., Yetts R. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg (Lond) 1983, 90:107-115.
10. Davies J.R., Grilli E.A. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989, 102:325-333.
11. Virelizier J.L. Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 1975, 115:434-439.
12. Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997, 159:95-103.
13. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61:94-99.
14. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 2008, 26(Suppl. 4):D5-D9.
15. Ambrose C.S., Wu X., Belshe R.B. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010.
16. David S., Skowronski D., Tweed S., Tuk T., Danderfer G., Li Y., et al. Epidemiologic profile of a new H3N2 variant of influenza A mismatched to vaccine, 2003-2004 influenza season. Can Commun Dis Rep 2005, 31:21-31.
17. Baldo V., Baldovin T., Pellegrini M., Angiolelli G., Majori S., Floreani A., et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010, 2010:517198.
18. Jackson L.A., Gaglani M.J., Keyserling H.L., Balser J., Bouveret N., Fries L., et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010, 10:71.
19. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
20. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
21. + T cells directed against H5N1 influenza virus. J Immunol 2008, 180:1758-1768.
22. Ge X., Tan V., Bollyky P.L., Standifer N.E., James E.A., Kwok W.W. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010, 84:3312-3319.
23. Subbramanian R.A., Basha S., Shata M.T., Brady R.C., Bernstein D.I. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 2010, 28:8258-8267.
24. Teijaro J.R., Verhoeven D., Page C.A., Turner D., Farber D.L. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 2010, 84:9217-9226.
25. + T cells is inefficient in the absence of B cells. J Virol 1998, 72:882-885.
26. Patel A., Tran K., Gray M., Li Y., Ao Z., Yao X., et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27:3083-3089.
27. Rao S.S., Kong W.P., Wei C.J., Van Hoeven N., Gorres J.P., Nason M., et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS One 2010, 5:e9812.
28. Van Reeth K., Braeckmans D., Cox E., Van Borm S., van den Berg T., Goddeeris B., et al. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccine 2009, 27:6330-6339.
29. + T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Hum Immunol 2010, 71:957-963.
30. Roederer M., Nozzi J.L., Nason M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011, 79:167-174.
31. Kiecker F., Streitz M., Ay B., Cherepnev G., Volk H.D., Volkmer-Engert R., et al. Analysis of antigen-specific T-cell responses with synthetic peptides - what kind of peptide for which purpose?. Hum Immunol 2004, 5:523-536.
32. Yager E.J., Ahmed M., Lanzer K., Randall T.D., Woodland D.L., Blackman M.A. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med 2008, 205:711-723.
33. Ely K.H., Roberts A.D., Kohlmeier J.E., Blackman M.A., Woodland D.L. Aging and CD8+ T cell immunity to respiratory virus infections. Exp Gerontol 2007, 42:427-431.
34. Deng Y., Jing Y., Campbell A.E., Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004, 172:3437-3446.
35. Czesnikiewicz-Guzik M., Lee W.W., Cui D., Hiruma Y., Lamar D.L., Yang Z.Z., et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008, 127:107-118.
36. Goronzy J.J., Lee W.W., Weyand C.M. Aging and T-cell diversity. Exp Gerontol 2007, 42:400-406.
37. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008, 118:3478-3490.
38. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
39. Tamura S., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58:195-207.
40. Treanor J., Wright P.F. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 2003, 115:97-104.
41. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37:427-439.
42. Renegar K.B. Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci 1992, 42:222-232.
43. Jeon S.H., Arnon R. Immunization with influenza virus hemagglutinin globular region containing the receptor-binding pocket. Viral Immunol 2002, 15:165-176.
44. Gogolak P., Simon A., Horvath A., Rethi B., Simon I., Berkics K., et al. Mapping of a protective helper T cell epitope of human influenza A virus hemagglutinin. Biochem Biophys Res Commun 2000, 270:190-198.
45. + T cell responses to influenza vaccine. J Immunol 2004, 173:673-681.
46. Wang L., Pan X.D., Xie Y., Zhang G.B., Jiang M., Zheng L., et al. Altered CD28 and CD95 mRNA expression in peripheral blood mononuclear cells from elderly patients with primary non-small cell lung cancer. Chin Med J (Engl) 2010, 123:51-56.
47. Vallejo A.N. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005, 205:158-169.
48. Effros R.B. Loss of CD28 expression on T lymphocytes: a marker of replicative senescence. Dev Comp Immunol 1997, 21:471-478.
49. Saba I., Kosan C., Vassen L., Moroy T. IL-7R-dependent survival and differentiation of early T-lineage progenitors is regulated by the BTB/POZ domain transcription factor Miz-1. Blood 2011, 117:3370-3381.
50. Shen C.H., Ge Q., Talay O., Eisen H.N., Garcia-Sastre A., Chen J. Loss of IL-7R and IL-15R expression is associated with disappearance of memory T cells in respiratory tract following influenza infection. J Immunol 2008, 180:171-178.
51. Channappanavar R., Twardy B.S., Krishna P., Suvas S. Advancing age leads to predominance of inhibitory receptor expressing CD4 T cells. Mech Ageing Dev 2009, 130:709-712.
52. Focosi D., Bestagno M., Burrone O., Petrini M. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 2010, 87:107-116.
53. + T cells and their association with HIV-1-induced T cell dysfunction. J Immunol 2005, 175:8415-8423.
54. Brenchley J.M., Karandikar N.J., Betts M.R., Ambrozak D.R., Hill B.J., Crotty L.E., et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003, 101:2711-2720.
55. Kaplan R.C., Sinclair E., Landay A.L., Lurain N., Sharrett A.R., Gange S.J., et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011, 203:452-463.
56. Appay V., Fastenackels S., Katlama C., Ait-Mohand H., Schneider L., Guihot, et al. Old age and anti-CMV immunity are associated with altered T cell reconstitution in HIV-1 infected patients. AIDS 2011, 25:1813-1822.
57. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983, 309:13-17.
58. Nguyen H.H., Zemlin M., Ivanov I.I., Andrasi J., Zemlin C., Vu H.L., et al. Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire. J Virol 2007, 81:9331-9338.
59. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75:5141-5150.
60. Richard S.A., Viboud C., Miller M.A. Evaluation of Southern hemisphere influenza vaccine recommendations. Vaccine 2010, 28:2693-2699.
61. Steinhoff M.C. Influenza in young children: burden, immunisation, and policy. Lancet Infect Dis 2011, 11:2-3.
62. Henkle E., Steinhoff M.C., Omer S.B., Roy E., Arifeen S.E., Raqib R., et al. Incidence of influenza virus infection in early infancy: a prospective study in South Asia. Pediatr Infect Dis J 2011, 30:170-173.